FOBTs With Lower Detection Limits Increase the Colonoscopy Rates

Şen, Bayram; okcu, oguzhan; ARPA, Medeni; AKDOGAN, REMZI ADNAN

doi:10.56615/tkbd.2023.19

FOBTs With Lower Detection Limits Increase the Colonoscopy Rates

Bayram Şen, (Recep Tayyip Erdoğan Üniversitesi, Rize Eğitim ve Araştırma Hastanesi, Tıbbi Biyokimya, Rize, Türkiye)

Oğuzhan Okcu, (Recep Tayyip Erdoğan Üniversitesi, Rize Eğitim ve Araştırma Hastanesi, Tıbbi Biyokimya, Rize, Türkiye)

Medeni Arpa, (Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Rize, Türkiye)

Remzi Adnan Akdoğan (Recep Tayyip Erdoğan Üniversitesi, Rize Eğitim ve Araştırma Hastanesi, Gastroenteroloji, Anabilim Dalı, Rize, Türkiye)

Türk Klinik Biyokimya Dergisi

5 1

Yıl: 2023 Cilt: 21 Sayı: 3 Sayfa Aralığı: 145 - 154 Metin Dili: İngilizce DOI: 10.56615/tkbd.2023.19 İndeks Tarihi: 09-01-2024

FOBTs With Lower Detection Limits Increase the Colonoscopy Rates

Öz:

Aim: Colon cancer, accounting for almost 10% of all cancers in both genders worldwide, is the fourth most common cause of cancer-related deaths. Approximately 95% of cases are originated from adenomas. In recent years, early detection of colon-borne pathologies and precancerous changes have contributed to decreased mortality rates. Therefore, early diagnosis is necessary to prevent and treat colorectal cancer properly. We aimed to evaluate the correlation of fecal occult blood tests (FOBT) with different detection limits with colonoscopy results and the performance of the tests. Material and Methods: The consistency of 3 different immunochemical FOBT (iFOBT) with cutoff values of 10, 30, and 50 ng/mL, which were used in a tertiary university hospital laboratory at different time periods, with colonoscopy results were analyzed retrospectively. The sensitivity, specificity, positive and negative predictive values of tests determined for adenoma-adenocarcinoma, advanced neoplasia, adenocarcinoma. Results: We observed that as the cutoff values of FOBT increased, lesion detection rates decreased; 1/23, 5/22, 1/1 of the adenocarcinoma cases were not detected for the tests with detection limits of 10, 30, 50 ng/mL, respectively. The negative predictive values of the tests were above 97% for adenocarcinoma detection. Conclusion: Changing the detection limit of the FOBT affects performance. Lowering the detection limit will facilitate the detection of adenocarcinoma patients and increase the number of colonoscopies performed due to false positive results.

Anahtar Kelime: Adenocarcinoma Adenoma Colon Cancer Fecal Occult Blood Test FOBT

Saptama Limitleri Daha Düşük Olan GGK Testleri Kolonoskopi Sayısını Artırır

Öz:

Amaç: Dünya çapında her iki cinsiyette de tüm kanserlerin yaklaşık 10%'unu oluşturan kolon kanseri, kansere bağlı ölümlerin dördüncü en yaygın nedenidir. Vakaların yaklaşık 95%'i adenomlardan kaynaklanır. Son yıllarda, kolon kaynaklı patolojilerin ve kanser öncesi değişikliklerin erken tespiti, ölüm oranlarının düşmesine katkıda bulunmuştur. Bu nedenle, kolorektal kanseri önlemek ve uygun şekilde tedavi etmek için erken teşhis gereklidir. Farklı saptama limitleri olan gaitada gizli kan testlerinin (GGK) kolonoskopi sonuçları ile ilişkisini ve testlerin performanslarını değerlendirmeyi amaçladık Materyal ve Metod: Üçüncü basamak bir üniversite hastanesi laboratuvarında farklı zaman dilimlerinde kullanılan 10, 30 ve 50 ng/mL cut-off değerlerine sahip 3 farklı immünokimyasal GGK testinin kolonoskopi sonuçları ile uyumu retrospektif olarak incelendi. Adenom ve adenokanser, ileri neoplazi, adenokarsinom için testlerin sensitivite, spesifite, pozitif ve negatif prediktif değerleri belirlendi. Bulgular: GGK testinin cut-off değerleri arttıkça lezyon saptama oranlarının düştüğünü gözlemledik; Adenokarsinom vakalarının 1/23'ü, 5/22'si, 1/1'i tespit limitleri sırasıyla 10, 30, 50 ng/mL olan testlerde saptanmadı. Testlerin negatif prediktif değerleri adenokarsinom tespiti için 97%'nin üzerindeydi. Sonuç: GGK testi tespit limitinin değiştirilmesi performansı etkiler. Tespit limitinin düşürülmesi adenokarsinom hastalarının tespit edilmesini kolaylaştıracak beraberinde yanlış pozitif sonuçlar nedeniyle uygulanan kolonoskopi sayısını artıracaktır.

Anahtar Kelime: Adenokarsinom Adenom Kolon Kanseri Gaitada Gizli Kan Testi GGK

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Lu M, Luo X, Li N, Chen H, Dai M. Diagnostic Accuracy Of Fecal Occult Blood Tests For Detecting Proximal Versus Distal Colorectal Neoplasia: A Systematic Review And Meta-Analysis. Clin Epidemiol. 2019;11:943-954.
2. Holme Ø, Bretthauer M, Fretheim A, Odgaard−Jensen J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database of Systematic Reviews. 2013(9).
3. Rasmussen S, Haastrup PF, Balasubramaniam K, Elnegaard S, Christensen Rd, Storsveen MM, et al. Predictive values of colorectal cancer alarm symptoms in the general population: a nationwide cohort study. British journal of cancer. 2019;120(6):595-600.
4. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Costeffectiveness of colorectal cancer screening–an overview. Best Practice & Research Clinical Gastroenterology. 2010;24(4):439-49.
5. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Annals of internal medicine. 2009;150(3):162-9.
6. Zhu MM, Xu XT, Nie F, Tong JL, Xiao SD, Ran ZH. Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta−analysis. Journal of digestive diseases. 2010;11(3):148-60.
7. Park DI, Ryu S, Kim Y-H, Lee S-H, Lee CK, Eun CS, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. American Journal of Gastroenterology. 2010;105(9):2017-25.
8. Li JN, Yuan SY. Fecal occult blood test in colorectal cancer screening. Journal of digestive diseases. 2019;20(2):62-4.
9. Assis R. Rastreamento e vigilância do câncer colorretal: guidelines mundiais. GED gastroenterol endosc dig. 2011;30(2):62-74.
10. Saraceni AF, Azevedo R, Almeida CMG, Baraviera AC, Kiss DR, Almeida MG. Association of fecal occult blood tests results with colonoscopic findings in a general hospital and validation of the screening test. Journal of Coloproctology (Rio de Janeiro). 2019;39(2):121-6.
11. Jucá MJ, Assunção PRT, Hasten-Reiter Júnior HN. Fecal occult blood test and flexible rectosigmoidoscopy: tools for the screening of colorectal neoplasms in asymptomatic patients. Journal of Coloproctology (Rio de Janeiro). 2015;35(1):35-41.
12. Imperiale TF, Glowinski EA, Lin-Cooper C, Larkin GN, Rogge JD, Ransohoff DF. Five-year risk of colorectal neoplasia after negative screening colonoscopy. New England Journal of Medicine. 2008;359(12):1218-24.
13. Altenburg FL, Biondo-Simões MdLP, Santiago A. Pesquisa de sangue oculto nas fezes e correlação com alterações nas colonoscopias. Revista Brasileira de Coloproctologia. 2007;27(3):304-9.
14. Elsafi SH, Alqahtani NI, Zakary NY, Al Zahrani EM. The sensitivity, specificity, predictive values, and likelihood ratios of fecal occult blood test for the detection of colorectal cancer in hospital settings. Clinical and experimental gastroenterology. 2015;8:279.
15. Högberg C, Gunnarsson U, Cronberg O, Thulesius H, Lilja M, Jansson S. Qualitative faecal immunochemical tests (FITs) for diagnosing colorectal cancer in patients with histories of rectal bleeding in primary care: a cohort study. International Journal of Colorectal Disease. 2020;35(11):2035-40.
16. Yuan SY, Wu W, Fu J, Lang YX, Li JC, Guo Y, et al. Quantitative immunochemical fecal occult blood test for neoplasia in colon cancer screening. Journal of digestive diseases. 2019;20(2):78-82.
17. Chiu H-M, Hsu W-F, Chang L-C, Wu M-H. Colorectal cancer screening in Asia. Current gastroenterology reports. 2017;19(10):1-8.
18. van Roon AH, Wilschut JA, Hol L, van Ballegooijen M, Reijerink JC, Kranenburg LJ, et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clinical Gastroenterology and Hepatology. 2011;9(4):333-9.
19. Liles EG, Perrin N, Rosales AG, Smith DH, Feldstein AC, Mosen DM, et al. Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study. BMC cancer. 2018;18(1):1-10.
20. Zandoná B, Carvalho LPd, Schimedt J, Koppe DC, Koshimizu RT, Mallmann ACM. Prevalência de adenomas colorretais em pacientes com história familiar para câncer colorretal. Revista Brasileira de Coloproctologia. 2011;31(2):147-54.
21. Muinuddin A, Aslahi R, Hopman WM, Paterson WG. Relationship between the number of positive fecal occult blood tests and the diagnostic yield of colonoscopy. Canadian Journal of Gastroenterology. 2013;27(2):90-4.
22. Brooks DD, Winawer SJ, Rex DK, Zauber AG, Kahi C, Smith RA, et al. Colonoscopy surveillance after polypectomy and colorectal cancer resection. American family physician. 2008;77(7):995-1002.
23. Van Rossum L, Van Rijn A, Laheij R, Van Oijen M, Fockens P, Jansen J, et al. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. British Journal of Cancer. 2009;101(8):1274-81.
24. Gies A, Cuk K, Schrotz-King P, Brenner H. Direct comparison of diagnostic performance of 9 quantitative fecal immunochemical tests for colorectal cancer screening. Gastroenterology. 2018;154(1):93-104.

APA	Şen B, okcu o, ARPA M, AKDOGAN R (2023). FOBTs With Lower Detection Limits Increase the Colonoscopy Rates. , 145 - 154. 10.56615/tkbd.2023.19
Chicago	Şen Bayram,okcu oguzhan,ARPA Medeni,AKDOGAN REMZI ADNAN FOBTs With Lower Detection Limits Increase the Colonoscopy Rates. (2023): 145 - 154. 10.56615/tkbd.2023.19
MLA	Şen Bayram,okcu oguzhan,ARPA Medeni,AKDOGAN REMZI ADNAN FOBTs With Lower Detection Limits Increase the Colonoscopy Rates. , 2023, ss.145 - 154. 10.56615/tkbd.2023.19
AMA	Şen B,okcu o,ARPA M,AKDOGAN R FOBTs With Lower Detection Limits Increase the Colonoscopy Rates. . 2023; 145 - 154. 10.56615/tkbd.2023.19
Vancouver	Şen B,okcu o,ARPA M,AKDOGAN R FOBTs With Lower Detection Limits Increase the Colonoscopy Rates. . 2023; 145 - 154. 10.56615/tkbd.2023.19
IEEE	Şen B,okcu o,ARPA M,AKDOGAN R "FOBTs With Lower Detection Limits Increase the Colonoscopy Rates." , ss.145 - 154, 2023. 10.56615/tkbd.2023.19
ISNAD	Şen, Bayram vd. "FOBTs With Lower Detection Limits Increase the Colonoscopy Rates". (2023), 145-154. https://doi.org/10.56615/tkbd.2023.19

APA	Şen B, okcu o, ARPA M, AKDOGAN R (2023). FOBTs With Lower Detection Limits Increase the Colonoscopy Rates. Türk Klinik Biyokimya Dergisi, 21(3), 145 - 154. 10.56615/tkbd.2023.19
Chicago	Şen Bayram,okcu oguzhan,ARPA Medeni,AKDOGAN REMZI ADNAN FOBTs With Lower Detection Limits Increase the Colonoscopy Rates. Türk Klinik Biyokimya Dergisi 21, no.3 (2023): 145 - 154. 10.56615/tkbd.2023.19
MLA	Şen Bayram,okcu oguzhan,ARPA Medeni,AKDOGAN REMZI ADNAN FOBTs With Lower Detection Limits Increase the Colonoscopy Rates. Türk Klinik Biyokimya Dergisi, vol.21, no.3, 2023, ss.145 - 154. 10.56615/tkbd.2023.19
AMA	Şen B,okcu o,ARPA M,AKDOGAN R FOBTs With Lower Detection Limits Increase the Colonoscopy Rates. Türk Klinik Biyokimya Dergisi. 2023; 21(3): 145 - 154. 10.56615/tkbd.2023.19
Vancouver	Şen B,okcu o,ARPA M,AKDOGAN R FOBTs With Lower Detection Limits Increase the Colonoscopy Rates. Türk Klinik Biyokimya Dergisi. 2023; 21(3): 145 - 154. 10.56615/tkbd.2023.19
IEEE	Şen B,okcu o,ARPA M,AKDOGAN R "FOBTs With Lower Detection Limits Increase the Colonoscopy Rates." Türk Klinik Biyokimya Dergisi, 21, ss.145 - 154, 2023. 10.56615/tkbd.2023.19
ISNAD	Şen, Bayram vd. "FOBTs With Lower Detection Limits Increase the Colonoscopy Rates". Türk Klinik Biyokimya Dergisi 21/3 (2023), 145-154. https://doi.org/10.56615/tkbd.2023.19